Chemical Namedupilumab
Dosage FormInjection(subcutaneous; 200 mg/1.14 ml, 300 mg/2 ml)
Drug ClassMonoclonal antibodies
SystemSkin, Respiratory
CompanyRegeneron Pharmaceuticals
Approval Year2017


  • To treat moderate-to-severe atopic dermatitis in patients ≥ 12 years of age in cases where topical prescription therapies are not viable or successful.
  • To maintain treatment of moderate-to-severe asthma in conjunction with other therapies in patients ≥ 12 years of age with an eosinophilic phenotype or with oral corticosteroid dependent asthma.
  • To maintain treatment of inadequately controlled chronic rhinosinusitis with nasal polyposis in conjunction with other therapies in adults.
Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Dupixent (Dupilumab) Prescribing Information 2017Regeneron Pharmaceuticals, Tarrytown, NY
Document TitleYearSource
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. 2018Journal of the European Academy of Dermatology and Venereology